Literature DB >> 25904266

Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults.

Shane A Gangatharan1, Manjula Maganti2, John G Kuruvilla1, Vishal Kukreti1, Rodger E Tiedemann1, Mary K Gospodarowicz3, David C Hodgson3, Alex Sun3, Richard W Tsang3, Melania Pintilie2, Michael Crump1.   

Abstract

Follicular lymphoma (FL) in young adults (YA, <40 years old) is uncommon, and the clinical characteristics and outcomes of this group are not well defined. We conducted a retrospective database review of 427 patients with newly diagnosed FL aged 65 years or less registered at Princess Margaret Cancer Centre between 1995 and 2010. YA (n = 61) and those 40-65 (n = 366) were compared with regards to clinical stage at diagnosis, FL International Prognostic Index (FLIPI) score, and the following clinical outcomes: time to second treatment, cause-specific survival (CSS) and overall survival (OS). At diagnosis, stage and FLIPI score were similar, as were the proportion of patients requiring therapy (YA 75% versus older adults 71%). Median follow-up was 8.1 years. Time to second therapy was similar in both age groups (5-year probability 23% YA versus 27% older adults; Gray's P-value = 0.76). Ten-year OS was significantly higher for YA (87% versus older adults 72%; P = 0.029). On multivariate analysis, age <40 years, low FLIPI score and observation as initial management were favourable prognostic factors for OS and CSS. We conclude that YA with FL have a favourable prognosis compared to older patients; whether this reflects competing mortality risks or age-related differences in lymphoma biology warrants further investigation.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer; chemotherapy; lymphomas; non-Hodgkin lymphoma; prognostic factors

Mesh:

Year:  2015        PMID: 25904266     DOI: 10.1111/bjh.13451

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.

Authors:  C Casulo; B Day; K L Dawson; X Zhou; C R Flowers; C M Farber; J D Hainsworth; J R Cerhan; B K Link; A D Zelenetz; J W Friedberg
Journal:  Ann Oncol       Date:  2015-09-11       Impact factor: 32.976

Review 2.  Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How.

Authors:  Francesca Pavanello; Sara Steffanoni; Michele Ghielmini; Emanuele Zucca
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-11-07       Impact factor: 2.576

3.  Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.

Authors:  Mariano Provencio; Pilar Sabín; Jose Gomez-Codina; Maria Torrente; Virginia Calvo; Marta Llanos; Josep Gumá; Cristina Quero; Ana Blasco; Miguel Angel Cruz; David Aguiar; Francisco García-Arroyo; Javier Lavernia; Natividad Martinez; Manuel Morales; Alvaro Saez-Cusi; Delvys Rodriguez; Luis de la Cruz; Jose Javier Sanchez; Antonio Rueda
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.